Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Craig M Kessler, MD
Georgetown University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Octapharma Research Site
Edmonton, Alberta, Canada
- Octapharma Research Site
St. John's, Newfoundland and Labrador, Canada
- Mcmaster University
Hamilton, Ontario, Canada
- University Hospital Centre Zagreb
Zagreb, Croatia
- Helsinki University Hospital
Helsinki, Finland
- Centre Régional de Traitement de L'Hémophilie
Bron, France
- Chu Estaing
Clermont-Ferrand, France
- Centre Hospitalier Universitaire Félix Guyon
La Réunion, France
- Centre Régional de Traitement de L'Hémophilie
Nantes, France
- Hôpital Purpan - Centre de Traitment Regional de L'Hemophilie Pole
Toulouse, France
- Nagoya University Hospital
Nagoya, Aichi-ken, Japan
- Hospital of the Univ of Occupational and Environmental Health
Kitakyushu, Fukuoka, Japan
- St. Marianna Univ School of Medicine Hospital
Kawasaki, Kanagawa, Japan
- Nara Medical University Hospital
Kashihara, Nara, Japan
- Gunma University Hospital
Maebashi, Japan
- Osaka National Hospital
Osaka, Japan
- Ogikubo Hospital
Tokyo, Japan
- Teikyo University Hospital
Tokyo, Japan
- University Medical Center Groningen
Groningen, Netherlands
- Phi Institute of Transfusion Medicine of Republic of Macedonia
Skopje, North Macedonia
- University Medical Centre Ljubljana
Ljubljana, Slovenia
- Octapharma Research Site
Sacramento, California, United States
- Octapharma Research Site
Aurora, Colorado, United States
- Octapharma Research Site
Washington D.C., District of Columbia, United States
- Octapharma Research Site
Miami, Florida, United States
- Octapharma Research Site
Chicago, Illinois, United States
- Octapharma Research Site
Indianapolis, Indiana, United States
- Octapharma Research Site
Memphis, Tennessee, United States
- Octapharma Research Site
Houston, Texas, United States
- Octapharma Research Site
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2015
- Primary completion
- 30 Sept 2018
- Completion
- 30 Sept 2018
- Last update posted
- 19 Jan 2021
- Registered enrollment
- 58
- Registry id
- NCT02256917
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.